Parkwalk Advisors is a London-based fund management firm managing investment-driven venture capital funds.
Parkwalk Advisors led the raise alongside a grant from Innovate UK to support the development of sleep technology applications.
"Smell can be our most powerful sense and only now are we realising the potential of technology to translate it for experience, welfare and health. This technology has enormous commercial applications which this new investment will help us unlock."
Parkwalk Advisors led the round with a £3.5m investment to fund new pediatric capabilities for the Censeo platform.
"Psyomics’ technology can help transform how we approach the assessment of mental health conditions not only in the UK but globally. Psyomics has an exciting pipeline of new technologies and services that will see it pioneer a more efficient approach to mental health diagnosis. It is an exceptional example of the contribution that the UK’s universities are making throughout healthcare, and we are delighted to help Psyomics scale and reach more people."
Parkwalk Advisors spearheaded the round to help the medical technology company prepare for human trials.
"With the support of our investors, we are on the cusp of revolutionising brain aneurysm treatment. Our team is dedicated to working with regulators, medical professionals, and industry experts to bring this product to market and address a condition impacting countless individuals worldwide."
Northern Gritstone and Parkwalk Advisors backed the seed round to support team expansion and product development.
"Medical devices follow a lengthy evaluation with a tiny amount of scientific evidence currently derived from computer modelling and simulation. The cost is ever-increasing, delaying lifesaving benefits to patients. Northern Gritstone’s and Parkwalk’s investment and support will enable adsilico to offer a scalable solution to the medical device market to produce evidence on an unprecedented scale"
The financing will support the advancement of proprietary in vivo reprogramming therapies through pre-clinical translation.
"We are delighted to receive the continued support of Astellas Venture Management, Parkwalk Advisors and other existing investors as we relentlessly focus on progressing our novel pipeline of in vivo reprogramming therapies through pre-clinical translation. Aligned to a consolidated corporate structure and vision, this latest funding will provide sufficient cash runway to enable the achievement of key development milestones in both our internal programs as well as those being developed in collaboration with strategic partners. Existing investor commitment is a testament to our delivery of world-class science, expertise in cellular reprogramming and the unique potential of the MOGRIFY platform to deliver novel regenerative medicines to improve the lives of a broad spectrum of patients."
